30 Background 31 Carbapenem resistant Enterobacterales (CRE) remain urgent antimicrobial resistance threats. 32 Approximately half of CRE clinical isolates lack carbapenem hydrolyzing enzymes and develop 33 carbapenem resistance through alternative mechanisms. The purpose of this study was to 34 elucidate the development of carbapenem resistance mechanisms from clonal, recurrent 35 extended-spectrum b-lactamase positive Enterobacterales (ESBL-E) bacteremia isolates in a 36 vulnerable patient population. 37 Methods 38 This study investigated a historical, retrospective cohort of ESBL-E bacteremia cases in the 39 University of Texas MD Anderson Cancer Center (MDACC) from January 2015 to July 2016. 40 Phylogenetic and comparative genomic analyses were performed to identify clonal, recurrent 41 ESBL-E isolates developing carbapenem resistance. Oxford Nanopore Technology (ONT) long-42 read and Illumina short-read sequencing data were used to generate consensus assemblies and to 43 identify signatures of mobile genetic element mediated amplification and transposition of 44 antimicrobial resistance genes. Serial passaging experiments were performed on a set of clinical 45 ST131 ESBL-E isolates to recapitulate in vivo observations. qPCR and qRT-PCR were used to 46 determine respective copy number and transcript levels of b-lactamase genes. 47 Results 48 116 ESBL-E bacteremia cases were identified, 16 of which had documented recurrent infections. 49 Four serial, recurrent isolates displayed a carbapenem resistant phenotype, three without the 50 acquisition of a known carbapenemase. These three isolates had non-carbapenemase-producing 51 CRE (non-CP-CRE) mechanisms driven by IS26-and ISEcp1-mediated amplification of 52 4 respective translocatable units (TU) and transposition units (TPU) harboring both blaOXA-1 and 53 blaCTX-M variants with concomitant outer membrane porin disruption. The TU and TPU 54 structures inserted into the open reading frames of outer membrane porin genes in a subset of 55 non-CP-CRE isolates. Serial passage of an index ST131 ESBL-E isolate under selective 56 carbapenem exposure resulted in chromosomal amplification of modular, TUs harboring β-57 lactamase genes with concomitant porin inactivation, recapitulating the in vivo carbapenem 58 resistance progression. Long-read sequencing of two additional MDACC bacteremia strains 59 identified similar non-CP-CRE mechanisms observed in the serial isolates. 60 Conclusions 61 Non-CP-CRE de novo mechanisms were the primary driver of CRE development in recurrent 62 bacteremia cases within this vulnerable patient population. The incorporation of long-read ONT 63 data into AMR surveillance platforms is critical to identify high-risk CRE isolates that are 64 difficult to identify with low-resolution phenotypic and molecular characterization methods. 65 66 Keywords: 67 Non-carbapenemase-producing carbapenem resistant Enterobacterales, Oxford Nanopore 68 Technologies MinION Sequencing, Mobile Genetic Element Amplifications, Mobile Genetic 69 Element Transpositions 70 71 5 BACKGROUND 72 Antimicrobial resistance (AMR) is an emerging global health priority and carbapenem resistant 73 Enterobacterales (CRE) are among the most serious AMR threats (1). Carbapenem resistance 74 can develop due to the acquisition of enzymes that hydrolyze carbapenems, known as 75 carbapenemases, as well as through changes in outer membrane permeability and/or drug efflux 76 activity, which decrease intracellular carbapenem concentrations (2). While most CRE research 77 has focused on characterizing carbapenemases (2), recent clinical and molecular epidemiology 78 studies indicate approximately 50% of CRE isolates are not carbapenemase carriers, suggesting a 79 substantial proportion of CRE isolates develop carbapenem resistance through alternative 80 mechanisms (3, 4). Molecular characterization of these alternative mechanisms indicate non 81 carbapenemase-producing carbapenem resistant Enterobacterales (non-CP-CRE) generally carry 82 extended-spectrum b-lactamases (ESBL) or AmpC-like enzymes with concomitant mutations 83 that alter porin function (2). Further studies reveal that Enterobacterales strains carrying outer 84 membrane porin mutations, but lacking ESBL or AmpC-like enzymes, develop de novo 85 carbapenem resistance at lower rates during serial passage under increasing carbapenem 86 concentrations (5, 6). Thus, the presence of ESBL or cephalosporinase genes may be a 87 component cause in non-CP-CRE development. Additionally, van Boxtel et al. demonstrated that 88 serial passaging of an ESBL or AmpC-producing isolate in the presence of a carbapenem can 89 result in amplification of plasmid-borne β-lactamase genes (7). Increased expression of the 90 narrow-spectrum TEM β-lactamases has similarly been reported to result in cefepime (8) and 91 piperacillin-tazobactam resistance (9-11), indicating that β-lactamase gene dosage is a factor in 92 increasing resistance to multiple b-lactam chemotherapies. These findings demonstrate 93 expression level and copy number of β-lactamases without known carbapenemase activity have 94 6 important effects on carbapenem susceptibility in porin deficient backgrounds (6, 7). 95
could not be discerned with this short-read sequencing analysis. This is due to inherent 118 limitations with short-read sequencing assemblers, which have difficulties resolving the 119 complex, repetitive mobile genetic elements (MGEs) that carry resistance genes (19) . Therefore, 120
we present an analysis utilizing Oxford Nanopore Technologies (ONT) MinION sequencing, a 121 long-read sequencing platform, which overcomes these limitations to elucidate these 122 amplification mechanisms. This study aims to track the de novo development of carbapenem 123 resistance mechanisms during recurrent Enterobacterales bacteremia infection by specifically 124 focusing on ESBL positive E. coli and K. pneumoniae strains and characterizing the non-CP-125 production was assessed per routine laboratory practice on E. coli, K. pneumonia, and K. oxytoca 141 isolates that were resistant to one or more oxyimino-cephalosporins (e.g. cefotaxime, 142 ceftriaxone, or ceftazidime) using either the ESBL Etest (bioMérieux) or the Rapid ESBL Screen 143 kit (ROSCO, Taastrup, Denmark) . Carbapenemase production was evaluated in the clinical lab 144 on any Enterobacterales isolate resistant to one more of the carbapenems using the Neo-Rapid 145 CARB kit (ROSCO) according to manufacturer's instructions. Carbapenem resistance (CR) was 146 defined as resistance to either ertapenem or meropenem using CLSI criteria (21) . Recurrent 147
Enterobacterales bacteremia was defined as identification of the same species in blood culture at 148 any point during the follow-up period following at least one negative blood culture and 149 completion of an antibiotic treatment regimen. 150 151 Illumina short-read sequencing 152 All available isolates from recurrent bacteremia patients, initially underwent whole genome 153 sequencing (WGS) via Illumina HiSeq as described previously (18) . The paired-end short-reads 154 were assessed using the FastQC toolkit (Babraham Institute), and adaptors as well as low-quality 155 reads were trimmed using Trimmomatic v0.33 (22) . Genome assembly was performed using 156 SPAdes v3.9.1 (23). Depth of short read mapping to individual genes of interest was quantitated 157 relative to the average read mapping depth for the pubMLST housekeeping gene schema for E. 158 coli ST10 and ST131 respectively. 159 160 Oxford Nanopore Technologies (ONT) long-read sequencing 161
Serial isolates that developed non-CP-CRE, isolates used in the serial passaging experiments, 162
and non-CP-CRE isolates from a previous study (18) underwent Oxford Nanopore Technologies 163 (ONT) long-read sequencing. Library preps were completed using the SQK-RBK004 rapid 164 barcoding kit with ~400 ng of input DNA and run on ONT MinION R9.4.1 flow cells using the 165 ONT GridION X5 (Oxford, UK) per manufacturer's instructions. ONT fast5 data was generated 166 using ONT MinKNOW software (v3.0.13) with subsequent base-calling using Guppy v3.2.2 167 software (Oxford, UK). qcat-v1.1.0 was used for read demultiplexing, read length filtering 168 (>1000 bp), and barcode removal (nanoporetech qcat GitHub: 169 https://github.com/nanoporetech/qcat). A custom python script was used for the generation of 170 polished, consensus assemblies (Shropshire, W flye_hybrid_assembly_pipeline GitHub: 171 https://github.com/wshropshire/flye_hybrid_assembly_pipeline 172 ). Briefly, the Flye-v2.5 (24) assembler was used for de novo assembly, and contigs were 173 circularized using berokka-v0.2 (Seemann, T berokka GitHub: 174 https://github.com/tseemann/berokka). The circlator v1.5.5 (25) 'clean' command was then used 175 to remove duplicate contigs sharing at least 90% identity. The remaining contigs were polished 176 with using the Oxford Nanopore long reads and then re-oriented with 177 Circlator (25) "fixstart" to standardize the chromosome to the dnaA gene. A second long-read 178 polish was then performed with .5 and these polished, corrected contigs were used as 179 input for Medaka v0.8.1 long-read polishing (nanoporetech medaka GitHub: 180 https://github.com/nanoporetech/medaka) followed by multiple rounds of Illumina short-read 181 polishing using . ONT assembly metrics are provided in Table S1 . 182 183 Phylogenetics, genetic variant calling, and clonality analysis 184 Phylogenetic analysis, in silico MLST, and subsequent variant-calling of serial isolates compared 185 against the index strain ONT consensus assembly were used to determine clonality. Initially, the 186 pan-genome pipeline tool was used to perform a core genome alignment of 187 the short-read SPAdes assemblies using the probabilistic alignment program PRANK (27, 28) . A 188 core genome pairwise SNP distance matrix was generated with these data using a custom Python 189 script (Narechania, A 190 GitHub:https://github.com/narechan/amnh/blob/master/bin/snp_matrixBuilder.pl), which was 191 subsequently used to build a maximum likelihood (ML) phylogenetic tree using . In silico multi-locus sequencing typing (MLST) was performed on the short-read SPAdes 193 assemblies using mlst-v2.15.1 (Seemann, T mlst Github: https://github.com/tseemann/mlst; (30). 194 Recurrent isolates that became non-CP-CRE were checked for clonality using the variant calling 195 pipeline tool Snippy-v4.3.6 (Seemann, T p4A passaging experiments with antibiotic selection were performed in LB broth under shaking 237 conditions at 37ºC. A single colony from the index strain of patient 4 (p4A) was grown 238 overnight, then diluted 1:100 into fresh LB containing ertapenem (ETP) (Sigma-Aldrich) at 0.5 239 MIC ETP. The process was repeated with increasing concentrations of ETP until growth was 240 observed at an ETP concentration of 32 µg/mL. Passaging experiments were performed twice 241 with growth occurring at an ETP MIC of ≥ 32 µg/mL within 3 passages (i.e. 72 hours) on each 242 occasion. For the first passaging experiment, cells were collected on four consecutive days 243 (strains p4A_1 to p4A_4) while continuing to passage at an ETP concentration of 32 µg/mL. 244
This was done in order to determine whether progressive β-lactamase encoding gene 245 amplification would be observed. On the second set of passaging experiments, cells were 246 collected on the first day that the ETP MIC reached ≥ 32 µg/mL, serially diluted onto agar plates, 247 and two different isolates were studied to assess for heterogeneity (strains p4A_H1 and 248 p4A_H2). Additional serial passaging experiments were conducted using p4C and p4D isolates 249 in the absence of antibiotic selection to determine the stability of the amplified units with 250 protocol adapted from previously published methods (37). 251 252
β-lactamase cloning and expression analysis 253
The open reading frames of b-lactamases were amplified from genomic DNA of the K. 254 pneumoniae strain MB101 using Q5 polymerase and the primers listed in Table S2 . Cloned 255 ORFs were inserted into the arabinose inducible vector pBAD33 by Gibson assembly (38) of 256 purified products. pBAD33blaCTX-M-15 and pBAD33blaOXA-1 were transformed into DH5a E. coli 257 and were maintained with 50 µg/mL chloramphenicol in cation adjusted Mueller Hinton (MHII) 258 media. MIC assays were performed with ceftriaxone (Sandoz GmbH), or piperacillin-tazobactam 259 (Fresenius Kabi USA) as follows. DH5α strains carrying pBAD33blaCTX-M-15, pBAD33blaOXA-1, 260 or control vector were grown for 18 hours at 220 rpm at 37 o C in MHII with 50 µg/mL 261 chloramphenicol. These cultures were diluted to approximately 5x10 5 CFU/mL in MHII with 262 0.2% L-Arabinose or vehicle control, without chloramphenicol. Each strain was exposed to serial 263 dilutions of the above drugs in microtiter plates sealed with gas-permeable membranes (Midsci). 264
Microtiter plates were incubated for 18 hours at 220 rpm at 37 o C, followed by OD600 265 measurement in a Biotek Synergy HT plate reader. The lowest tested antibiotic concentration 266 yielding OD600 measurement of 0.06 or less in at least two of three replicate wells was 267 considered to be the MIC. 268 269
Statistical analyses 270
All statistical analyses were performed using Stata v13. was assigned as a two-sided P value < 0.05. 278
Data availability 280
The index isolate assemblies from recurrent bacteremia patients that developed non-CP-CRE as 281 well as the long-read and short-read data for all isolates have been deposited in the National 282
Center for Biotechnology (NCBI) BioProject database PRJNA603908. ONT-sequencing data of 283 non-CP-CRE isolates from a previous study (18) Table S3 . E. coli was the most common 291 organism isolated (100/116; 86.2%), followed by K. pneumoniae (14/116; 12.1%), and K. 292 oxytoca (2/116; 1.7%). Carbapenems were used as primary treatment in 92% of index cases. 293
Recurrent bacteremia was identified in 16/116 (13.8%) patients and primarily occurred either in 294 patients with leukemia or recipients of hematopoietic stem cell transplants (14/16 cases, Table  295 S3). The majority (14/16) of recurrent bacteremia cases had E. coli isolated, with the remaining 296 two cases being due to K. pneumoniae infections. Carbapenem-resistant isolates were present in 297 4/16 (25%) recurrent bacteremia patients ( Fig. 1) . All four recurrent isolates that developed 298 carbapenem resistance were E. coli isolates from leukemia patients. The full set of serial isolates 299 was available for 11/16 (68.8%) patients, including all strains from the four patients that had at 300 least one recurrent isolate that developed a carbapenem resistant phenotype. 301 
Detection of non-CP-CRE emergence from three sets of clonal, ESBL-E recurrent 312 bacteremia isolates 313
The 11 sets of patient serial isolates included nine E. coli serial isolates and two K. pneumoniae 314 serial isolates. We performed Illumina short-read sequencing on the 26 strains identified from the 315 11 sets of serial isolates. Strain details are provided in Table S4 . Serial strain relatedness was 316 assessed using phylogenetic analysis with strains considered possibly clonal if they were the 317 same sequence type, had the same Bayesian population structure, and clustered together on the 318 phylogenetic tree (Fig. S1) . The temporal collection, antimicrobial resistance, and strain 319 relatedness are depicted in Fig. 1 . Only a single strain, the 3 rd isolate from patient 7, which we 320 will abbreviate as p7C, had a carbapenemase based on a positive Neo-Rapid CARB Kit Test 321 result ( Fig. 1) . Whole genome, short-read sequencing analysis confirmed the presence of the 322 class D carbapenemase, blaOXA-181 in p7C. Furthermore, p7C was a different sequence type from 323 the patient 7 index strain (p7A) indicating new strain acquisition. 324
325
We focused our subsequent analyses on the isolates from patient 4 (p4), patient 10 (p10), and 326 patient 11 (p11), as each had at least one carbapenem resistant recurring non-CP-CRE isolate. 327
Our HiSeq WGS data indicated that all three patients had recurrent E. coli isolates that 328 respectively clustered together within a core genome phylogenetic tree, had the same Bayesian 329 hierarchical population structure, and belonged to the same sequence type ( Fig. S1) . We 330 confirmed clonality by measuring pairwise SNP distances between each recurrent isolate and 331 their respective index strain using their highly resolved, ONT consensus assemblies. Our analysis 332 indicated that there were less than 20 SNPs for all respective recurrent strains relative to their 333 index strain suggesting that these three patients had clonal, re-infecting strains that had 334 developed carbapenem resistance through a non-carbapenemase mechanism ( Table 1) 
Gene amplification and porin loss associated with emergence of non-CP-CRE 353
Each of the serial isolates that developed a non-CP-CRE phenotype (p4A-D, p10A-C, and p11A-354 B) had increased Illumina short-read and ONT long-read coverage depth for β-lactamase 355 encoding genes indicating amplification (Fig. 2, Table S5 and Table S6 ). Specifically, we noted 356 increased coverage depth of blaOXA-1 in all p4 recurrent isolates, blaCTX-M-55 in p10 recurrent 357 isolates, and blaOXA-1and blaCTX-M-15 in both the index and recurrent isolate of p11 ( Table 1) . We 358 used qPCR to confirm the increased short-read and long-read coverage depth of our WGS 359 analyses and found that the increased coverage depth corresponded to increased transcript levels 360 of the amplified β-lactamase encoding genes (Fig. 2) . 361
362
We further characterized outer membrane porin genes with our sequencing data as disruptions of 363 these genes are often correlated with carbapenem resistance. The only consistently identified 364 variation in the non-CP-CRE strains relative to their ESBL-E index strains were mutations that 365 disrupted the ORFs of the porin proteins OmpC and OmpF ( Table 1) . The initial sequencing 366 results indicated that an insertion sequence (IS) as well as nucleotide deletions that resulted in 367 frame-shifts mediated ompC gene disruption in isolates that developed non-CP-CRE. 368
Conversely, we consistently found frame-shift inducing deletions in ompF genes for both the 369 carbapenem susceptible and resistant isolates ( Table 1) . For p10 isolates, interruption of OmpC 370 and OmpF in the second, non-CP-CRE isolate (p10B) was followed by reversion to the WT 371
OmpC and OmpF genes in the third, carbapenem-susceptible isolate (p10C). to endogenous control gene rpsL. RNA was collected from mid-exponential phase in triplicate on 379 two separate days (n = 6). Data shown are mean ± SD. (C, F) similar analysis to (B, E, H) except 380 that data are for blaCTX-M. Note that the p10 strains do not contain blaOXA-1. P values refer to 381 measurements in the serial isolates relative to initial isolate using the Kruskal-Wallis (p4 and 382 p10) or Wilcoxon rank-sum tests (p11). 383 384 Class 1 transposon TnMB1860 found in both ST131 p4 and p11 serial isolates. 385
The consensus ONT assembly index strains for patient 4 (p4A) and patient 11 (p11A) both 386 contain an 8,147 bp, IS26-mediated translocatable unit (TU), designated as MB1860TU_A, 387 which carries blaOXA-1, and inserts upstream adjacent to another 3,985 bp TU, designated 388 MB1860TU_B, that carries blaCTX-M-15 ( Fig. 3A) . MB1860TU_C is the combination of both 389 respective TUs that is 12,132 bp in length. The entire putative class 1 transposon structure 390 designated TnMB1860 is 12,952 bp ( Fig. 3A) . 391 392 When moving from the 5' to 3' end of TnMB1860 using the p4A chromosome ( Fig. 3A ; 393 GenBank Accession #: CP049085) as the reference, the first resistance island contains two 394 flanking IS26 tnpA genes in opposite orientation with the aminoglycoside N6'-acetyltransferase 395 variant gene (aac(6')-Ib-cr), the oxacillinase gene (blaOXA-1), and a truncated chloramphenicol 396 resistance determinant (ΔcatB3). Following the second IS26 element in TnMB1860, there is an 397 aminoglycoside N3'-acetyltransferase III variant gene, aacC3, and the tunicamycin resistance 398 gene, tmrB. Downstream of the tmrB gene is an IS3 element, which has a modified left inverted 399 repeat (IRL) and a frame-shifted transposase that has been truncated by a third IS26 element at 400 the 3' end of the IS3 transposase. Immediately downstream of this IS26 element is a truncated 401
Tn2-like transposase which marks the 3' boundary of MB1860TU_A. MB1860TU_A is inserted 402 adjacent to the smaller translocatable unit, MB1860TU_B, which includes another fragment of a 403
Tn2-like transposase, as well as orf477, blaCTX-M-15, and an ISEcp1 truncated by an intact IS26, 404 which marks the 3' boundary of both MB1860TU_B, as well as serves as the 3' flanking IS26 405 element for the full length TnMB1860. Similar IS26/Tn2 family transposable elements that have 406 putatively formed via homologous recombination events have previously been reported in 407 association with IS26-mediated AMR transfer in Enterobacterales (6, 39, 40) . 408 409 TnMB1860 is located on the p4 chromosome (1,764,660 -1,777,611 bp; GenBank Accession #: 410 CP049085) and the p11 chromosome (1,812,524 -1,825,475 bp; GenBank Accession #: 411 CP049077). One of the signatures of transposition are variable sized direct repeats called target 412 site duplications (TSDs) that flank insertion sequences and are created during the transposition 413 process (41-43). The TnMB1860 composite transposon on the p11A chromosome has 7-bp TSDs 414 that indicate a transposition within a 3,762 bp ORF that putatively is involved in molybdopterin 415 cofactor biosynthesis (Fig. S2) . Interestingly, p4A differs in chromosomal context relative to 416 p11A due to an intramolecular transposition event that occurred in reverse orientation (Fig. S3) . 417 This is evidenced by the fact that p4A has an approximately 61 kbp region that is inverted with a 418 downstream IS26 in inverse orientation that has an 8-bp TSD within the colicin I receptor gene, 419 cirA, in reverse complement orientation (Fig. S3 ). An alignment of p4A and p11A with two 420 other E. coli ST131 chromosomes, TO217 (GenBank Accession #: LS992192.1) and 421
Ecol_AZ146 (GenBank Accession #: CP018991.1) indicate similar chromosomal carriage of 422
TnMB1860 with the noted inversion event that has occurred in the p4A isolate (Fig. S3) . Patient 11 isolates p11A and p11B had relatively the same increase in mapping coverage for both 452
blaOXA-1 and blaCTX-M-15 (Table S3 ). The consensus assemblies of both p11 isolates revealed that 453 this increase in relative short-read coverage was due to two copies of blaOXA-1 and blaCTX-M-15 454 being present on a chromosomally located TnMB1860 as well as on IS26-mediated genomic 455 resistant modules present on a 180,963bp multireplicon, F-type plasmid, p11A_p2 (Fig. S2, Fig.  456 S3; GenBank Accession #: CP049079). The CRE phenotype of p11B relative to p11A appears to 457 be driven by additional inactivation of the ompC gene given that the ompF gene is truncated in 458 both strains (Table 1) . 459
460
In contrast to the p11 isolates, the amplification and transposition of the modular, translocatable 461 units that compose TnMB1860 in p4 was completely in a chromosomal context (Fig. 3) . There 462 was a consistent increase in short-read coverage depth (Fig. 3A) of the entire MB1860TU_A 463 structure up to approximately 23-fold in p4D relative to the seven housekeeping pubMLST genes 464 for ST131. We first analyzed strain p4B, which had developed resistance to piperacillin-465 tazobactam (TZP) but remained carbapenem susceptible ( Table 1 ). In p4B, MB1860TU_A 466 generated a ~10X tandem array in situ most likely through a conservative, IS26-mediated 467 transposition mechanism or homologous recombination ( Fig. 3B) (44, 45) . We were unable to 468 assemble the full-length tandem array due to limitations in read length size. However, we were 469 able to use the SVAnts tool to identify thirty individual reads with two or greater number of 470 tandem arrays of MB1860TU_A with 7 individual reads having 4X copies of blaOXA-1. The 471 occurrence of the 10X TU amplification at the original TnMB1860 locus was confirmed by 472 aligning the p4B long-reads to the reference chromosome p4A using SVAnts in conjunction with 473 a short-read pileup analysis. Additionally, all outer membrane protein genes were WT and 474 remained intact with p4B. Given that p4B had developed resistance to TZP relative to p4A 475 (Table 1) , we sought to determine whether overexpression of blaOXA-1 could drive TZP 476 resistance. Inducing blaOXA-1 expression through cloning under an arabinose responsive promoter 477 increased TZP MIC 6.8-fold relative to uninduced cells (Fig. S4) . 478 479 Next, we examined the non-CP-CRE serial strains p4C and p4D. Interestingly, in both p4C and 480 p4D a transposition and insertion of MB1860TU_A into ompC was present approximately 63 481 kbp upstream of the original TnMB1860 chromosomal locus (Fig. 3B) . This ompC gene 482 disruption was confirmed through the identification of multiple p4C long-reads > 30 kbp that 483 covered the full transposition site as well as identifying this insertion on the p4C and p4D 484 incomplete chromosomal assemblies. We found two individual long reads that were able to span 485 the full length of the MB1860TU_A array (3X copies) which disrupts ompC for p4C and 486 confirmed the exact MB1860TU insertion location within ompC (c.504_505ins; Table 1 ). We 487 also were able to identify 8-bp TSDs ('5-TTGCTGTT-3') at each end of the ompC insertion 488 sites, which indicates MB1860TU_A replicative transposition. The p4D assembly and individual 489 long-reads indicated a second MB1860TU_A transposition and insertion ~67 kbp downstream of 490 the TnMB1860 within a GH25 lysozyme gene (Fig. 3B) . This transposition event could be 491 confirmed by 8-bp TSDs (5'-TTGCTGTT-3') flanking the full insertion site (Fig 3B) . A 492 progressive increase in both DNA and RNA levels for blaOXA-1 but not blaCTX-M-15 in the p4 serial 493 isolates was confirmed using qPCR and qRT-PCR, respectively ( Fig. 2A-C) . 494 495
Serial passage of patient 4 index strain with ETP elicits blaOXA-1 and blaCTX-M-15 496 amplification through unique translocatable units relative to in vivo recurrent strains 497
We passaged strain p4A in increasing concentration of ertapenem (ETP) to determine whether 498 antimicrobial exposure was driving the genetic changes observed in our serial clinical isolates. 499
Resistance to ETP developed within three passages corresponding to three days, upon which we 500 collected strains for the next four days (p4A_1-p4A_4). Short-read and qPCR analyses 501 demonstrated all four isolates had amplification of both blaOXA-1 and blaCTX-M-15 relative to the 502 p4A index strain prior to ETP exposure (Fig 4) . ONT sequencing on all four isolates indicated 503 that similar to p4B, there was in situ amplification occurring at the original TnMB1680 504 chromosomal locus. However, the full-length TU, MB1860TU_C, which consists of 505 MB1860TU_A and MB1860TU_B (Fig 4A) that harbor blaOXA-1 and blaCTX-M-15 respectively, 506 was the amplifying structure for the passaged isolates in contrast to what we saw in the in vivo 507 isolates where MB1860TU_A was the sole amplifying structure ( Table 2) . 508 We repeated the experiment and again found that ETP resistance developed within three 511 passages from the p4A isolate. ONT sequencing of the 2 nd round of passaged isolates (p4A_H1 512 and p4A_H2) revealed amplification of MB1860TU_B that harbors blaCTX-M-15 solely, which we 513 verified using qPCR (Fig. 4) . Similar to what we observed in vivo, the serially passaged ETP 514 resistant isolates contained inactivating mutations in ompC although we did not observe any 515 MB1860TU mediated interruptions ( Table 2) . INDELs inactivating the ompF gene were 516 observed in a fraction of the serial isolates suggesting ompF inactivation may not be necessary 517 for the development of non-CP-CRE ( Table 2) . We found that p4A responded in vitro to ETP 518 similarly to what was observed in our serial clinical isolates by amplification of modular 519 MB1860TU elements with concomitant porin disruption. Nevertheless, there was differential 520 amplification of IS26 translocatable units demonstrating the modularity of these MGEs. 521
522
In order to determine the chromosomal stability of the MB1860TU tandem arrays in the absence 523 of antibiotic selective pressure, both ertapenem resistant (ETP-R) strains p4C and p4D were 524 passaged for 10 days (~60 generations) without supplemented ertapenem. Both ETP-R recurrent 525 strains consistently maintained carbapenem resistance through 60 generations of growth (Fig.  526   S5) . The p4C and p4D strains had relative copy number decreases of blaOXA-1 from 33 to 18X 527 (45% decrease) and 53 to 42X (21% decrease) respectively (Fig. S5) . These results indicate that 528 both adapted strains can have persisting carbapenem resistance with associated tandem arrays of 529 amplified blaOXA-1 maintained in the absence of antibiotic exposure. coli isolates Compared to the p4 and p11 strains, the serial isolates from patient 10 (p10A -545 p10C) contain a different MGE that putatively drives the amplification of the ESBL encoding 546 gene, blaCTX-M-55. Index strain p10A harbors blaCTX-M-55 located on an ISEcp1 transposition unit 547 designated EC215TPU that resides on a multireplicon FIB-FIC-FII plasmid (Fig. 5; GenBank  548 Accession #: CP049082). 'Transposition unit' (TPU) is used here to distinguish from 549 translocatable unit (TU) as they have different transposition mechanisms that are mediated by 550 ISEcp1 and IS26 respectively. There are three additional small plasmids present in p10A, one of 551 which is a ColE1-like 6.8 kbp plasmid designated as p10A_p2 (GenBank Accession #: 552 CP049083), that is highly comparable to pCERC1 (GenBank Accession #: JN012467) (46). 553 554 EC215TPU translocates from the multireplicon, type F plasmid in p10A, designated p10A_p1, to 555 p10A_p2 in the second serial isolate p10B (Fig. 5B) . The ISEcp1-mediated transposition can be 556 identified and confirmed by the 5-bp TSDs that are immediately upstream of the ISEcp1 14 bp 557 IRL and downstream of another alternative, 14 bp right inverted repeat (IRRalt) respectively (41, 558 42, 47) . There are TSDs flanking EC215TPU at the p10A_p2 recombination site with both the 559 IR:L and IRRalt represented as a blue triangle (5'-CCTCACACCTTCGA-3') on Fig. 5B.  560 Notably, as the entire insertion region with three blaCTX-M-55 copies on p10B has 5 bp TSDs (5'-561 GATAT-3') that flank IRL and IRRalt respectively, one can postulate that an amplification event 562 occurred on p10A_p1, which then subsequently inserted into p10A_p2 (Fig. 5B) . p10B is also 563 the only carbapenem-resistant p10 serial isolate. This likely is due in part to deletions in ompC 564 and ompF that create frame-shift truncations of each respective porin in contrast to the WT 565 genotypes of each respective porin found in p10A and p10C. When analyzing the third isolate 566 p10C, there only is one copy of blaCTX-M-55 identified in the assembly and short-reads on 567 p10A_p2. However, the short-read and long-read coverage depth analysis suggests an increase in 568 copy number (Table S6 ). The subsequent increase in initiation RNA genes, a marker for ColE1-569 like plasmids with blaCTX-M-55 suggests that p10C amplification occurs by an increase in the 570 overall copy number of p10A_p2. These data are consistent with our qPCR analysis which 571 demonstrate progressively higher DNA levels of blaCTX-M-55 for each serial isolate (Fig. 2) . There were two non-CP-CRE strains, MB101 (K. pneumoniae) and MB746 (E. coli), identified 595 in a previous study examining the role of short-read WGS in predicting β-lactam resistance 596 (Table 1) (18) . We performed ONT sequencing on the two isolates to determine whether 597 mechanisms of gene amplification and porin disruption were similar to what was observed in the 598 cohort of non-CP-CRE bacteremia serial isolates. Both isolates contain IS26-mediated TUs 599 carrying blaOXA-1 as previously characterized in TnMB1860 (Fig. 6) . 600 601 For strain MB101 (Fig. 6A-B) , a ST37 K. pneumoniae isolate, the ~9310 bp IS26-mediated TU, 602 designated MB101TU harbors aac-(6')-Ib-cr, blaOXA-1, ΔcatB3, aacC3, and tmrB and is nearly 603 identical (100% coverage; 99.9% ID) to MB1860TU_A found in serial E. coli isolates from 604 patients 4 and 11 (Fig. 6A) . An ISEcp1-mediated TPU harboring blaCTX-M-15, designated 605 MB101TPU, was also present on the MB101 chromosome as well as an FIBK type plasmid, with 606 at least five copies present on the chromosome based on the Flye assembly and individual long 607 reads. The assembly and long reads indicate the transposition of MB101TPU into a putative 608 glycoporin encoding gene which was followed by the transposition of MB101TU to an existing 609 IS26 element downstream of MB101TPU (Fig. 6A) . We identified an amplification of 610 MB101TU at this locus that created a tandem array of at least 8X copies based on the 611 identification of multiple long-reads with multiple MB101TU copies. Interestingly, there was 612 also a transposition event of MB101TPU into the ompK36 encoding gene, a homolog of ompC in 613 E. coli (Fig. 6B) . Thus, MB101 has amplification of both blaOXA-1 and blaCTX-M-15 via distinct 614 mechanisms along with TPU mediated porin disruption. 615
616
The ST405 E. coli isolate, MB746, has an IS26-mediated translocatable unit, designated 617 MB746TU, which also includes a genomic resistance module that carries aac(6')-Ib-cr, blaOXA-1, 618 and a truncated chloramphenicol resistance determinant (Fig. 6C-D) similar to what is seen on 619 MB1860TU_A. MB746TU carries an additional tetracycline resistance operon and macrolide 620 resistance operon, not present on TnMB1860. We found four individual long-reads that carried at 621 least 3X copies of MB746TU present in the same MB746 chromosomal location (Fig. 6C) . 622
Additionally, we identified a FIB plasmid that harbored both blaOXA-1 and blaCTX-M-15 which has a 623 similar configuration and orientation to TnMB1860 (Red bracket; Fig. 6D) . The IS26-mediated 624 TU carrying blaCTX-M-15 has 99.7% BLAST identity with MB1860_B with the only substantial 625 difference being a size of 5558 bp vs the 3985 bp MB1860TU_B (Fig. 6D) . Notably, MB746 626 also had ompC and ompF gene disruptions ( Table 1) While recent systematic surveillance studies indicate that the prevalence of non-CP-CRE 649 remains high (3, 4) , the mechanisms contributing to non-CP-CRE emergence within clinical 650 settings are largely unknown. This public health issue is particularly troublesome given the 651 difficulties in properly diagnosing non-CP-CRE infections and prescribing effective 652 antimicrobials due to the transient nature of their carbapenem resistance phenotypes as well as 653 their lack of a carbapenemase. This analysis demonstrates that multiple TU-and TPU-mediated 654 modular amplifications of β-lactamase encoding genes in conjunction with porin inactivation are 655 driving non-CP-CRE emergence in our cohort of cancer patients with recurrent bacteremia . It is 656 well established that "copy-in" replicative transposition is a common mechanism by which IS26-657 mediated TUs mobilize to regions lacking a pre-existing IS26 element (43, 45, 48) . Recent 658 studies have shown that TUs can create tandem resistance gene arrays by targeting genomes with 659 an existing copy of IS26 through an intermolecular, conservative transposition mechanism and, 660 less frequently, through RecA-dependent homologous recombination (43) (44) (45) 49) . We were able 661 to determine that the initial incorporation of the composite transposon TnMB1860 as well as 662 MB1860TU_A transposition into ompC and the predicted glycoside hydrolase gene occurred 663 through a replicative transposition mechanism based on characteristic TSDs at insertion sites. 664
The amplification of MB1860TU_A, MB1860TU_B, and MB1860TU_C that created tandem 665 arrays of resistance genes observed in our study likely occurred through a conservative 666 transposition mechanism although RecA-dependent homologous recombination could also be 667 contributing to the generation of these tandem arrays. The ability to detect genetic structures 668 capable of amplifying b-lactamase encoding genes that synergistically insert into porin encoding 669 genes will be essential for diagnostic and surveillance purposes in order to ensure we are 670 properly identifying clinical isolates that have the ability to develop CRE. blaOXA-1 in 147/149 E. coli strains, primarily ST131 isolates, suggesting that many E. coli 676 isolates carrying blaOXA-1 may be capable of this amplification (40, 50) . The finding that blaOXA-1 677 amplification was consistently associated with progressive development of β-lactam resistance 678 was somewhat surprising given that this enzyme is typically considered a narrow spectrum β-679 lactamase (51). However, overexpression of blaOXA-1 using an arabinose inducing promoter was 680 shown to generate resistance to ertapenem in a porin deficient strain (6) there have been only two other reports of an ISEcp1-mediated TPU harboring a β-lactamase 719 encoding gene causing the disruption of a porin, in both cases OmpK35 from K. pneumoniae (57, 720 58) . While there have been a number of studies that have implicated IS-mediated porin 721 disruptions, including IS26 mediated disruptions (54, 59-61), to our knowledge, this is the first 722 documented IS26-mediated translocatable unit disruption of an outer membrane porin followed 723 by amplification of a b-lactamase gene. Given the length of the TUs, as well as the fact that they 724 have the ability to amplify and create tandem arrays once inserted into the porin encoding genes, 725 it is unlikely that targeted PCR based strategies or commonly used short-read approaches alone 726 would have been able to identify the full extent of the TUs observed in our study. Thus, 727 performing long read sequencing on larger cohorts of Enterobacterales with porin deficient 728 backgrounds should reveal whether TU/TPUs harboring AMR genes are a frequent mediator of 729 porin gene disruption, but have not been previously identified due to the long and repetitive 730 nature of the involved DNA structures. 731
732
The clinical impact of β-lactamase gene amplification and porin loss driving carbapenem 733 resistance has been postulated to be mitigated by the fitness costs imposed on the organism by 734 such genetic changes (37, (62) (63) (64) . However, such AMR mechanisms are increasingly being 735 recognized as commonly occurring in clinical isolates, including in the serious infections 736 described in our cohort (37, (62) (63) (64) . This would suggest that organisms with the capability to 737 amplify AMR genes are widespread and capable of causing significant human infections 738 especially under antibiotic selective pressure (7, 9, 10, 65) . Moreover, the most recent systematic 739 data on CRE in the U.S. found no difference in outcomes between patients with CRE and non-740 CP-CRE suggesting that circulating non-CP-CRE organisms may not have significant fitness 741 defects (4). Furthermore, our own results from serial passaging p4C and p4D without ETP 742 exposure suggests these amplified structures harboring AMR genes associated with increased 743
MICs to ertapenem and meropenem may be fairly stable in the absence of antibiotic selective 744 pressure. The chromosomal context of TnMB1860 may provide insights into the stability of this 745 structure as a previous study had noted stable transposon carriage when mobilized from plasmid 746 to chromosome at very low levels of antibiotic exposure (66). 747
748
In addition to possibly imposing a fitness cost on the organism, AMR gene amplifications have 749 also been associated with the presence of antimicrobial heteroresistance (65, 67) . The interplay 750 between AMR gene amplification, heteroresistance and fitness is likely reflected in the genotype 751 changes of patient 10 isolates given the development and subsequent reversion of porin 752 mutations observed in those strains (Table 1) . Recent systematic surveys have indicated 753 approximately 25% of strains reported as carbapenem resistant tested as susceptible at a central 754 laboratory, likely reflecting the transient phenomenon of AMR heteroresistance (4, 64). A 755 limitation of our study is that we only sequenced a single colony for each isolate, which almost 756 certainly underestimates the genetic complexity of a bacterial population responding to 757 antimicrobial therapy. Nevertheless, a challenge presents itself in capturing population 758 heterogeneity with a single genome assembly as multiple, heterogeneous sequencing reads will 759 break current assembler algorithms. 760
761

CONCLUSIONS 762
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